According to GlobalData’s Pharma Intelligence Center Pipeline Drugs Database, there are 21 peptide drugs in development for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of Acute Respiratory Distress Syndrome (ARDS) and other ...Learn More

Recently, Biomarck Pharmaceuticals, Ltd.announced the a Phase 2a clinical results of BIO-11006 for patients with ARDS (Acute Respiratory Distress Syndrome). The 38-patient study met the primary endpoint of no significant increase in serious adverse events, and reduced all-cause ...Learn More